into the pain treatment market. From the acquisition, King gained the patents on the pain management drugs, Flector and Embeda. They also gained a completely separate animal health division, which focuses on the many agricultural and animal health needs of livestock animals. Acquisition On October 12, 2010, Pfizer Inc. () announced it would acquire Bristol-based King Pharmaceuticals, Inc. for a total cost to Pfizer of $3.6 billion in cash or $14.25 per share. The acquisition was expected to expand Pfizer's product line of pain relief and management medication by adding King products such as Embeda, Avinza, and the Flector Patch. Other product lines that made King attractive to Pfizer included the EpiPen for emergency delivery of medications and the Alpharma animal health line. References External links King Pharmaceuticals "FundingUniverse.com - King Pharmaceuticals, Inc. - Company History (see Altace and Hoechst)" Pharmaceutical companies disestablished in 2010 Companies formerly listed on the New York Stock Exchange Defunct pharmaceutical companies of the United States Health care companies based in Tennessee Defunct companies based in Tennessee Pfizer Life sciences industry 2010 mergers and acquisitions Bristol, Tennessee Pharmaceutical companies established in 1994